Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New Approaches
- 23 March 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Asthma
- Vol. 49 (4), 416-422
- https://doi.org/10.3109/02770903.2012.668255
Abstract
Objective. The efficacy of omalizumab in severe asthma has been widely demonstrated. The main objective of this study was to evaluate the efficacy and tolerability of omalizumab in a real-life setting in Spain, particularly in those patients with immunoglobulin E (IgE) levels out of range. Methods. Totally 266 uncontrolled severe asthma patients receiving high-dose inhaled corticosteroids (ICSs) plus long-acting β2-agonist (LABA) were recruited. Main efficacy outcomes were asthma exacerbation rate (AER), asthma control test (ACT), and global evaluation of treatment effectiveness (GETE). Results. AER was reduced from 3.6 (3.6) in previous year to 0.67 (1.2) at 4 months (p < .05) and to 1.04 (1.8) at 2 years (p < .05). ACT increased significantly from 14.3 (4.7) at baseline to 18.4 (4.4) at 4 months (p < .05) and to 20.3 (4.0) (p < .05) at 2 years. After 4 months, 74.6% of patients had reached a good or excellent rate on the GETE scale (p < .05). This rate continued increasing up to 81.6% at 2 years. These efficacy results were similar for patients with “off-label” IgE > 700 IU/ml. At follow-up, maintenance treatment with oral steroids was discontinued in a considerable number of patients: from 89 to 19 (p < .05). Omalizumab was discontinued because of lack of efficacy only in 28/266 (10.5%) patients. Overall, 30 patients (11.4%) reported adverse events. Severe adverse events were not observed. Conclusion. This real-life study confirms that omalizumab is very efficacious and very well tolerated in patients with uncontrolled severe asthma. Results did not vary in the subgroup of patients with IgE levels >700 IU/ml.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City ChildrenThe New England Journal of Medicine, 2011
- Italian real-life experience of omalizumabRespiratory Medicine, 2010
- “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST studyRespiratory Medicine, 2009
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespiratory Medicine, 2009
- The use of omalizumab in the treatment of severe allergic asthma: A clinical experience updateRespiratory Medicine, 2009
- Effectiveness of omalizumab (Xolair®) in the first patients treated in real-life practice in FranceRespiratory Medicine, 2008
- How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respiratory Medicine, 2005
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Can Guideline-defined Asthma Control Be Achieved?American Journal of Respiratory and Critical Care Medicine, 2004